Use of genetically modified viruses and genetically engineered virus-vector vaccines: environmental effects
- PMID: 16982535
- DOI: 10.1080/15287390600751405
Use of genetically modified viruses and genetically engineered virus-vector vaccines: environmental effects
Abstract
Despite major therapeutic advances, infectious diseases remain highly problematic. Recent advancements in technology in producing DNA-based vaccines, together with the growing knowledge of the immune system, have provided new insights into the identification of the epitopes needed to target the development of highly targeted vaccines. Genetically modified (GM) viruses and genetically engineered virus-vector vaccines possess significant unpredictability and a number of inherent harmful potential hazards. For all these vaccines, safety assessment concerning unintended and unwanted side effects with regard to targeted vaccinees has always been the main focus. Important questions concerning effects on nontargeted individuals within the same species or other species remain unknown. Horizontal transfer of genes, though lacking supportive experimental or epidemiological investigations, is well established. New hybrid virus progenies resulting from genetic recombination between genetically engineered vaccine viruses and their naturally occurring relatives may possess totally unpredictable characteristics with regard to host preferences and disease-causing potentials. Furthermore, when genetically modified or engineered virus particles break down in the environment, their nuclei acids are released. Appropriate risk management is the key to minimizing any potential risks to humans and environment resulting from the use of these GM vaccines. There is inadequate knowledge to define either the probability of unintended events or the consequences of genetic modifications. The objective of this article is to highlight the limitations in environmental risk assessment and raise awareness of the potential risks involving the use of genetically modified viruses and genetically engineered virus-vector vaccines.
Similar articles
-
Biological safety concepts of genetically modified live bacterial vaccines.Vaccine. 2007 Jul 26;25(30):5598-605. doi: 10.1016/j.vaccine.2006.11.058. Epub 2006 Dec 5. Vaccine. 2007. PMID: 17239999 Review.
-
Pox viruses as eukaryotic cloning and expression vectors: future medical and veterinary vaccines.Prog Vet Microbiol Immunol. 1988;4:197-217. Prog Vet Microbiol Immunol. 1988. PMID: 3078866 Review.
-
Recombinant viruses obtained from co-infection in vitro with a live vaccinia-vectored influenza vaccine and a naturally occurring cowpox virus display different plaque phenotypes and loss of the transgene.Vaccine. 2004 Dec 9;23(4):499-506. doi: 10.1016/j.vaccine.2004.06.032. Vaccine. 2004. PMID: 15530698
-
Safety and nutritional assessment of GM plants and derived food and feed: the role of animal feeding trials.Food Chem Toxicol. 2008 Mar;46 Suppl 1:S2-70. doi: 10.1016/j.fct.2008.02.008. Epub 2008 Feb 13. Food Chem Toxicol. 2008. PMID: 18328408 Review.
-
Development and registration of recombinant veterinary vaccines. The example of the canarypox vector platform.Vaccine. 2007 Jul 26;25(30):5606-12. doi: 10.1016/j.vaccine.2006.11.066. Epub 2006 Dec 8. Vaccine. 2007. PMID: 17227690 Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources